IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 239 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.52 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,807,324 | -54.4% | 1,276,335 | -29.4% | 0.00% | -50.0% |
| Q2 2023 | $12,732,171 | -46.7% | 1,808,547 | -53.7% | 0.00% | -60.0% |
| Q1 2023 | $23,878,069 | +43.9% | 3,908,031 | +50.5% | 0.01% | +66.7% |
| Q4 2022 | $16,595,098 | +144.4% | 2,597,042 | +266.4% | 0.00% | +200.0% |
| Q3 2022 | $6,790,000 | -78.8% | 708,832 | -75.6% | 0.00% | -87.5% |
| Q2 2022 | $32,023,000 | +148.8% | 2,900,624 | +275.3% | 0.01% | +166.7% |
| Q1 2022 | $12,869,000 | +2.3% | 772,906 | +17.3% | 0.00% | 0.0% |
| Q4 2021 | $12,581,000 | -71.1% | 659,058 | -62.7% | 0.00% | -66.7% |
| Q3 2021 | $43,576,000 | -39.2% | 1,767,063 | -35.9% | 0.01% | -43.8% |
| Q2 2021 | $71,706,000 | +113.3% | 2,755,764 | +159.5% | 0.02% | +100.0% |
| Q1 2021 | $33,618,000 | -57.1% | 1,061,819 | -37.1% | 0.01% | -61.9% |
| Q4 2020 | $78,387,000 | +66.3% | 1,689,392 | +18.0% | 0.02% | +61.5% |
| Q3 2020 | $47,145,000 | -18.9% | 1,432,098 | -32.4% | 0.01% | -38.1% |
| Q2 2020 | $58,113,000 | +253.7% | 2,117,046 | +285.7% | 0.02% | +162.5% |
| Q1 2020 | $16,432,000 | +8.5% | 548,915 | +0.4% | 0.01% | +14.3% |
| Q4 2019 | $15,138,000 | +62.3% | 546,884 | +6.7% | 0.01% | +75.0% |
| Q3 2019 | $9,327,000 | -35.4% | 512,519 | -13.0% | 0.00% | -33.3% |
| Q2 2019 | $14,444,000 | -21.7% | 589,047 | -69.6% | 0.01% | -33.3% |
| Q1 2019 | $18,439,000 | -53.3% | 1,938,868 | -56.6% | 0.01% | -57.1% |
| Q4 2018 | $39,506,000 | +4.0% | 4,464,013 | +32.2% | 0.02% | +23.5% |
| Q3 2018 | $37,978,000 | +489.5% | 3,375,861 | +570.8% | 0.02% | +466.7% |
| Q2 2018 | $6,442,000 | +62.2% | 503,235 | +114.2% | 0.00% | +50.0% |
| Q1 2018 | $3,971,000 | +1047.7% | 234,975 | +444.6% | 0.00% | – |
| Q4 2017 | $346,000 | -32.6% | 43,144 | -34.8% | 0.00% | – |
| Q3 2017 | $513,000 | – | 66,124 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Perceptive Advisors | 11,826,299 | $130,562,000 | 4.09% |
| MPM BioImpact LLC | 1,200,000 | $13,248,000 | 3.68% |
| Finepoint Capital LP | 960,200 | $10,601,000 | 3.66% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 3,011 | $273,000,000 | 2.85% |
| Avoro Capital Advisors LLC | 9,220,000 | $101,789,000 | 2.01% |
| Long Focus Capital Management, LLC | 1,625,000 | $17,940,000 | 1.88% |
| 683 Capital Management, LLC | 2,000,000 | $22,080,000 | 1.56% |
| Parametrica Management Ltd | 115,870 | $1,268,000 | 1.38% |
| Boxer Capital, LLC | 1,935,133 | $21,364,000 | 1.35% |
| Soleus Capital Management, L.P. | 719,600 | $7,944,000 | 1.24% |